VYNE Therapeutics shares are trading higher after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.

VYNE THERAPEUTICS INC -2.33%

VYNE THERAPEUTICS INC

VYNE

2.12

-2.33%

VYNE Therapeutics shares are trading higher after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via